The transformative Inflation Reduction Act of 2022 is the number one trend IQVIA is following this year. Discover how the complex dynamics of Medicare Part D redesign will drive liability increases for both biopharma manufacturers and insurers. Such liabilities are expected to lead to tighter payer control and challenge brands’ gross-to-net.


With less than a year on the market, Mounjaro is already performing like few other medications we have seen in the past decade. Unpacking this remarkable launch makes it clear that Mounjaro isn’t just an outlier; it is a torchbearer for an entirely new category of medicine and demonstrates the shifting (or blurring) line between consumer and medical avenues of care.
Transitional assistance is now part of the standard launch brand toolkit, but little research has been conducted on the impact that these programs have on long-term brand success. Using a selection of GLP-1s as an entry point, this blog measures the role and impact of manufacturer-sponsored patient support at launch and beyond.
Market Access Insights
Navigating the market access and financial landscape
The path to the market access summit can be steep, winding, and, at times, unclear. From navigating the complexities of payer requirements to disruption from the Inflation Reduction Act of 2022, you require the best equipment, knowledge, and insights to climb with confidence and reach the apex of your products’ potential.
On the horizon
Top Trends to Watch in 2023
2023 is poised to be an important inflection point for much of healthcare in the United States: New strategies and technologies for educating and engaging healthcare providers, rising expectations, but stagnating engagement from patients, and a shifting legislative and regulatory landscape.
What do we see on the horizon that you need to know? Tap into our 2023 trends below.
See the whole board
The Inflation Reduction Act of 2022 is poised to be a watershed event for the U.S. healthcare system, setting up a complex chess game for pharmaceutical manufacturers.
In this brief, a team of IQVIA industry experts – from policy and market access to brand strategy and financial planning – establish the contours of the conversation and elucidate both short-term impact and long-term implication.
A real-time conversation on launch
IQVIA Monthly Launch Tracker
What products are leading the launch pack? Is the therapy area mix changing? What key markets are bucking trends and creating a new normal? Tap into the IQVIA Monthly Launch Tracker for this and more. Data updated through September 2023.
.............................................................................................................
IQVIA U.S. Launch Landscape
In this and future issues, we will rigorously investigate the past and present in an effort to understand the future.
- What is the definition of launch success?
- Is there an optimal way to engage and educate providers on new products?
- What is the impact of patient behavior, access, and affordability?
- How much can a launch-naïve company rely on historical norms versus brave new pathways?
Up. Down. Or sideways.
The healthcare world is moving in diverse directions. Discover the latest trends, what’s pushing and pulling the market, and what you can do to break from the pack.
Ten Med Tech Trends to Watch in 2023
2023 presents new uncertainties as optimism generated by a gradual recovery from the upheaval of COVID-19 is being met with new challenges such as staffing shortages, energy market disruptions, and rising interest rates.
.............................................................................................................U.S. Pharmaceutical Market Trends Report
A monthly report tracking healthcare treatment and utilization trends, including prescription volumes, medical claims activity, and deep dives into oncology and HCP engagement.
The Use of Medicines in the U.S. 2023
Usage and spending trends and outlook to 2027
Areas of focus in this year’s report range from looking at health system utilization and its recovery from the pandemic, to how medicine usage patterns have shifted, the complex nature of drug pricing, and the impact of out-of-pocket costs on patients.
